viewPolarean Imaging PLC

Polarean Imaging PLC - Total Voting Rights

RNS Number : 5159L
Polarean Imaging PLC
30 April 2020

Polarean Imaging Plc

("Polarean" or the "Company") 


Total Voting Rights


Polarean Imaging plc (AIM: POLX), the medicalimaging technology company, with a proprietary drugdevice combination product for the magnetic resonance imaging (MRI) market, announces that the total number of shares in issue and total voting rights as at the date of this announcement is 161,295,607 ordinary shares of £0.00037 each.


The total issued share capital of the Company consists of 161,295,607 Ordinary Shares. This number may be used by Shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.



Polarean Imaging plc  

www.polarean.com / www.polarean-ir.com  

Richard Hullihen, Chief Executive Officer 

Via Walbrook PR  




SP Angel Corporate Finance LLP  

Tel: +44 (0)20 3470 0470   

David Hignell / Soltan Tagiev (Corporate Finance) 


Vadim Alexandre / Rob Rees (Corporate Broking) 





Walbrook PR  

Tel: +44 (0)20 7933 8780 or [email protected]  

Paul McManus / Anna Dunphy  

Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Polarean Imaging PLC

Price: 32.4

Market: AIM
Market Cap: £52.43 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Polarean Imaging in commercial launch mode for its lung function scanner

Polarean Imaging PLC's (LON:POLX) Richard Hullihen caught up with Proactive London's Andrew Scott following a recent pre-NDA meeting with the FDA. He says they're targeting the third quarter of this year to submit an NDA for its drug-device combination which uses hyperpolarised 129-Xenon gas...

2 weeks, 3 days ago